Загрузка...

The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo

Multiple myeloma (MM), a hematologic malignancy of terminally differentiated plasma cells is closely associated with induction of osteolytic bone disease, induced by stimulation of osteoclastogenesis and suppression of osteoblastogenesis. The ubiquitin-proteasome pathway regulates differentiation of...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Pennisi, Angela, Li, Xin, Ling, Wen, Khan, Sharmin, Zangari, Maurizio, Yaccoby, Shmuel
Формат: Artigo
Язык:Inglês
Опубликовано: 2009
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC2612734/
https://ncbi.nlm.nih.gov/pubmed/18980173
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.21310
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!